Nanotechnology-based combinatorial anti-glioblastoma therapies: moving from terminal to treatable
Aggressive glioblastoma (GBM) has no known treatment as a primary brain tumor. Since the cancer is so heterogeneous, an immunosuppressive tumor microenvironment (TME) exists, and the blood–brain barrier (BBB) prevents chemotherapeutic chemicals from reaching the central nervous system (CNS), therape...
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Publicado em: |
Multidisciplinary Digital Publishing Institute
2022
|